[ad_1]
Incyte will acquire Escient Pharmaceuticals, a clinical-stage company specializing in neurosensory-inflammatory disorders, for $750 million. Incyte will get Escient’s lead drugs, the small molecules EP262 and EP547. EP262 is being developed to treat chronic urticaria and atopic dermatitis, while EP547 is targeted at cholestatic and uremic pruritus. The drugs could launch as early as 2029, Incyte’s CEO Hervé Hoppenot says in a press release.
[ad_2]
Source link
